Showing 4201-4210 of 7411 results for "".
- KYTHERA Biopharmaceuticals, Inc. Names F. Michael Ball to Boardhttps://practicaldermatology.com/news/20130925-kythera_biopharmaceuticals_inc_names_f_michael_ball_to_board/2459451/KYTHERA Biopharmaceuticals, Inc. has named F. Michael (Mike) Ball, Chief Executive Officer (CEO) of Hospira, Inc. to its Board of Directors. Mr. Ball brings more than 25 years of healthcare experience to KYTHERA. Mr. Ball was appointe
- Elevator Pitch Sessions Launching from The Medical Entrepreneurhttps://practicaldermatology.com/news/20130924-elevator_pitch_sessions_launching__from_the_medical_entrepreneur/2459454/The Medical Entrepreneur Symposium is introducing a one day event on Saturday December 7 in Delray Beach. The “Elevator Pitch Sessions” will be geared towards helping physicians learn how to fund their next venture. "We are excite
- ResurFX for M22 Platform from Lumenis Receives FDA Clearancehttps://practicaldermatology.com/news/20130917-resurfx_for_m22_platform_from_lumenis_receives_fda_clearance/2459459/The FDA recently granted 510(k) clearance for ResurFX, a new fractional non-ablative laser module from Lumenis. ResurFX is the latest application module for the company's M22 platform, expanding its capabilities to perform true fractional non-ablative skin resurfacing.
- GSK Receives FDA Priority Review for Dabrafenib/Trametinib Combination in Metastatic Melanomahttps://practicaldermatology.com/news/20130916-gsk_receives_priority_review_from_fda_for_dabrafenibtrametinib_combination_in_metastatic_melanoma/2459460/The FDA has granted priority review designation to GlaxoSmithKline's supplemental New Drug Applications (sNDAs) for combined use of Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 E or
- Data for PV-10 in Melanoma to be Presented at European Cancer Congresshttps://practicaldermatology.com/news/20130913-data_for_pv-10_in_melanoma_to_be_presented_at_european_cancer_congress/2459461/Analysis of data from Provectus Pharmaceuticals, Inc.'s completed Phase 2 study of intralesional PV-10 in metastatic melanoma will be presented at the upcoming European Cancer Congress (ECCO 17- ESMO-38 - ESTRO 32), taking place September 27 through
- Exuviance Launches Age Less Everyday Daily Moisturizerhttps://practicaldermatology.com/news/20130912-exuviance_launches_age_less_everydaydaily_moisturizer/2459462/NeoStrata Company, Inc., recently introduced Exuviance Age Less Everyday, a daily moisturizer formulated to correct the signs of aging for skin that is dry, sensitive, or easily impacted by everyday stressors. Exuviance Age Less Everyday is formulated w
- Caliber Imaging & Diagnostics Introduces VivaScope 1500 Multilaser Systemhttps://practicaldermatology.com/news/20130910-caliber_imaging__diagnostics_introduces_vivascope_1500_multilaser_system/2459465/Caliber Imaging & Diagnostics, formerly Lucid, Inc., recently introduced the VivaScope 1500 Multilaser system, cellular imaging devices that give researchers the option of a painless, no
- Sensus Healthcare Appoints Dr. Mark Nestor as Clinical Directorhttps://practicaldermatology.com/news/20130830-sensus_healthcare_appoints_dr_mark_nestor_as_clinical_director/2459470/Mark Nestor, MD, PhD has been appointed as Clinical Director of Sensus Healthcare. Dr. Nestor will lead the company's efforts in the areas of training, education, and clinical research as Se
- FDA Approves Mirvaso for Treating Facial Erythema of Rosaceahttps://practicaldermatology.com/news/20130826-fda_approves_mirvaso_for_treating_facial_erythema_of_rosacea/2459476/The FDA recently approved Mirvaso (brimonidine) gel, 0.33% for the topical treatment of the facial erythema of rosacea in adults 18 years of age or older. According to manufacturer Galderma Laboratories, applied once
- Merz North America Appoints New Chief Financial Officerhttps://practicaldermatology.com/news/20130807-merz_north_america_appoints_new_chief_financial_officer/2459482/Merz North America has appointed John Donofrio as Chief Financial Officer and Head of Business Development - North America. In this role, Donofrio will be primarily accountable for financial performance, cost management, and strategic business planning and analysis for the Finance organization in No